Supplementary Table S10 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Harshabad Singh(Brigham and Women's Hospital), Andrew J. Aguirre(Broad Institute), Matthew B. Yurgelun(Dana-Farber Cancer Institute), Kevin S. Kapner(Broad Institute), James M. Cleary(Brigham and Women's Hospital), Rishi Surana(Dana-Farber Cancer Institute), Srivatsan Raghavan(Broad Institute), Lauren K. Brais(Dana-Farber Cancer Institute), Andrew D. Cherniack(Broad Institute), Michael H. Rosenthal(Brigham and Women's Hospital), Julien Dilly(Massachusetts Institute of Technology), Annacarolina da Silva(Cornell University), Douglas A. Rubinson(Harvard University), Elizabeth F. Cohen(Dana-Farber Cancer Institute), Geoffrey I. Shapiro(Brigham and Women's Hospital), Chen Yuan(Qingdao University), Brian M. Wolpin(Harvard University), Marios Giannakis(Broad Institute), Matthew Meyerson(Broad Institute), Jonathan A. Nowak(Brigham and Women's Hospital), Benjamin L. Schlechter(Brigham and Women's Hospital), Elizabeth Andrews(Dana-Farber Cancer Institute), Hersh Gupta(Dana-Farber Cancer Institute), Yvonne Li(Broad Institute), Kimmie Ng(Dana-Farber Cancer Institute), Valentina Nardi(Biopredic (France)), Jason L. Hornick(Harvard University), Thomas E. Clancy(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Michael Tolstorukov(Dana-Farber Cancer Institute), Rachel B. Keller(Dana-Farber Cancer Institute), Kimberly Perez(Brigham and Women's Hospital)
Cited by 0
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
The Immune Landscape of Cancer
|Immunity|2018|6.2k